Saint Louis University

SLUCare dermatologists are committed to leadership in clinical research programs. As the faculty of Saint Louis University School of Medicine, our staff regularly conducts clinical trials of new medicine and technologies.

Pemphigus vulgaris study:

SLUCare Dermatology is now seeking patients 18-75 years of age who have had a confirmed diagnosis of pemphigus vulgaris (PV) within the past 24 months. Call (314) 256-3439 or email for more information.

Chin filler study:

SLUCare Dermatology is also conducting a study of an investigational filler that adds chin volume to improve the appearance of the chin. Participants must be age 22 or older, in good general health and not pregnant. Call (314) 256-3439 or email for more information. 

Psoriasis study for children 2-11:

We are looking for children who are at least 2 to 11 years of age with psoriasis to participate in an 8-week research study of an investigational medication for psoriasis.

Qualified participants will receive:

  • Study-related medical evaluations by a dermatologist
  • Study-related medications
  • Compensation for time and travel

For more information, call Dr. Anastasia Kurta at (314) 256-3454 or

Psoriasis study for children 6-11:

SLUCare physicians at SSM Health Cardinal Glennon Children's Hospital are conducting a clinical research study of children with moderate-to-severe plaque psoriasis. The CADMUS Jr. clinical research study will examine the safety and effectiveness of an investigational medication in children with this skin condition.

The study will enroll patients who:

  • Are 6 to 11 years of age
  • Have a diagnosis of plaque psoriasis for at least 6 months

Additional criteria apply and will be assessed at the screening visit.

To learn more, contact SLU Dermatology Research (Dr. Ashley McWilliams) at
(314) 256-3454 or

Psoriasis study for adults 18 and older:

We are looking for adults age 18 and older in good general health, but with moderate to severe plaque psoriasis.The purpose is to evaluate and compare the safety and effectiveness of two FDA-approved injectable medications for treatment of psoriasis.

You may be eligible if you meet the physician-evaluated and laboratory criteria for treatment and agree to complete all study required visits and to prevent pregnancy for the length of the study.

The study will last up to 56 weeks and will include multiple visits to the study site. Eligible participants if enrolled may receive the following:

  • Study treatment
  • Laboratory testing
  • Research related exams
  • Compensation for time and travel 

For more information, call Dr. Anastasia Kurta at (314) 256-3454 or

Learn more

To learn about other current trials, call the research office at (314) 256-3454 or email